...
首页> 外文期刊>Journal of Korean medical science. >Validity of Outcome Prediction Scoring Systems in Korean Patients with Severe Adult Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation Therapy
【24h】

Validity of Outcome Prediction Scoring Systems in Korean Patients with Severe Adult Respiratory Distress Syndrome Receiving Extracorporeal Membrane Oxygenation Therapy

机译:严重成人呼吸窘迫综合征接受体外膜氧合治疗的韩国患者结局预测评分系统的有效性

获取原文
   

获取外文期刊封面封底 >>

       

摘要

Recently, several prognostic scoring systems for patients with severe acute respiratory distress syndrome (ARDS) requiring extracorporeal membrane oxygenation (ECMO) have been published. The aim of this study was to validate the established scoring systems for outcome prediction in Korean patients. We retrospectively reviewed the data of 50 patients on ECMO therapy in our center from 2012 to 2014. A calculation of outcome prediction scoring tools was performed and the comparison across various models was conducted. In our study, the overall hospital survival was 46% and successful weaning rate was 58%. The Predicting Death for Severe ARDS on V-V ECMO (PRESERVE) score showed good discrimination of mortality prediction for patients on ECMO with AUC of 0.80 (95% CI 0.66-0.90). The respiratory extracorporeal membrane oxygenation survival prediction (RESP) score and simplified acute physiology score (SAPS) II score also showed fair prediction ability with AUC of 0.79 (95% CI 0.65-0.89) and AUC of 0.78 (95% CI 0.64-0.88), respectively. However, the ECMOnet score failed to predict mortality with AUC of 0.51 (95% CI 0.37-0.66). When evaluating the predictive accuracy according to optimal cut-off point of each scoring system, RESP score had a best specificity of 91.3% and 66.7% of sensitivity, respectively. This study supports the clinical usefulness of the prognostic scoring tools for severe ARDS with ECMO therapy when applying to the Korean patients receiving ECMO. Go to: Graphical Abstract
机译:最近,已发布了几种需要体外膜氧合(ECMO)的严重急性呼吸窘迫综合征(ARDS)患者的预后评分系统。这项研究的目的是验证韩国患者结局预测的既定评分系统。我们回顾性研究了2012年至2014年间我们中心50例接受ECMO治疗的患者的数据。进行了结果预测评分工具的计算,并对各种模型进行了比较。在我们的研究中,整体医院生存率为46%,成功断奶率为58%。 V-V ECMO(PRESERVE)评分对严重ARDS的死亡预测显示出对ECMO患者的AUC为0.80(95%CI 0.66-0.90)的死亡率预测具有良好的判别能力。呼吸道体外膜氧合存活预测(RESP)评分和简化的急性生理学评分(SAPS)II评分也显示出合理的预测能力,其中AUC为0.79(95%CI 0.65-0.89)和AUC为0.78(95%CI 0.64-0.88) , 分别。但是,ECMOnet评分未能预测死亡率,AUC为0.51(95%CI为0.37-0.66)。根据每个评分系统的最佳分界点评估预测准确性时,RESP评分的最佳特异性分别为敏感性的91.3%和66.7%。这项研究支持将ECMO疗法用于严重ARDS的预后评分工具在应用于接受ECMO的韩国患者时的临床实用性。转到:图形摘要

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号